Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.

@article{Hughes2010IntramuscularIB,
  title={Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.},
  author={Richard A. C. Hughes and Kenneth C. Gorson and D. Cros and Jeffrey D. Griffin and J Pollard and Jean-michel Vallat and S L Maurer and Katherine Riester and Gudarz Davar and Keith Dawson and Alfred Sandrock},
  journal={Neurology},
  year={2010},
  volume={74 8},
  pages={
          651-7
        }
}
OBJECTIVE Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) shares immunologic features with multiple sclerosis (MS). Because IM interferon beta-1a (IM IFNbeta-1a) is an effective and safe treatment for MS, we conducted a dose-ranging efficacy study of IFNbeta-1a in patients with CIDP. METHODS Adults with IV immunoglobulin (IVIg)-dependent CIDP (n = 67) were enrolled in this 32-week double-blind trial and randomized to IM IFNbeta-1a. Patients received 30 microg once weekly plus… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 37 CITATIONS

An update on the management of chronic inflammatory demyelinating polyneuropathy.

  • Therapeutic advances in neurological disorders
  • 2012
VIEW 3 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS